Home

John Furey

CIK 1691218 · Chief Operating Officer · last filed 2026-06-16

John Furey is a Chief Operating Officer who has filed 15 SEC Form 4 insider transactions across 4 companies since 2016. The most recent filing, for PCVX, was dated Jun 16, 2026. Across all open-market trades the lifetime net is −$3.2M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $309.3K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$309.3K

Companies

4

Total Filings

15

Lifetime Open-Market Net

-$3.20M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
PCVX Director 5,306 $58.29 $309.3K $0 3 2026-06-16
Adaptimmune Therapeutics PLC (ADAP) Delisted Director — $0.06 — $0 5 2024-07-01
ASND Director — $255.62 — $0 1 2019-07-03
Spark Therapeutics, Inc. (ONCE) Delisted Chief Operating Officer 18 — — -$3.20M 6 2018-04-24

Recent Filings

15 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-16 PCVX Grant (A) +2,265 $0 EDGAR
2025-06-16 PCVX Grant (A) +3,041 $0 EDGAR
2024-07-03 PCVX Grant (A) — $0 EDGAR
2024-07-01 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2023-07-03 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2022-07-01 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2021-07-02 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2020-07-01 Adaptimmune Therapeutics PLC (ADAP) Delisted Grant (A) — $0 EDGAR
2019-07-03 ASND Grant (A) — $0 EDGAR
2018-04-24 Spark Therapeutics, Inc. (ONCE) Delisted Mixed — -$220.2K EDGAR
Showing 1–10 of 15
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.